002390 信邦制药
交易中 06-02 13:39:06
资讯
新帖
简况
信邦制药（002390）披露2025年度股东会决议公告，5月13日股价下跌0.61%
证券之星 · 05-13
信邦制药（002390）披露2025年度股东会决议公告，5月13日股价下跌0.61%
股市必读：信邦制药（002390）5月11日披露最新机构调研信息
证券之星 · 05-12
股市必读：信邦制药（002390）5月11日披露最新机构调研信息
每周股票复盘：信邦制药（002390）Q1净利增17.97%
证券之星 · 05-03
每周股票复盘：信邦制药（002390）Q1净利增17.97%
信邦制药(002390)3月31日股东户数7.04万户，较上期减少4.68%
证券之星 · 04-29
信邦制药(002390)3月31日股东户数7.04万户，较上期减少4.68%
图解信邦制药一季报：第一季度单季净利润同比增长17.97%
证券之星 · 04-28
图解信邦制药一季报：第一季度单季净利润同比增长17.97%
信邦制药：公司本报告期非经常性损益的主要构成为投资收益与子公司税率变化
证券之星 · 04-24
信邦制药：公司本报告期非经常性损益的主要构成为投资收益与子公司税率变化
信邦制药：公司2025年综合毛利率较去年同期略有上升
证券之星 · 04-23
信邦制药：公司2025年综合毛利率较去年同期略有上升
信邦制药(002390)3月31日股东户数7.04万户，较上期减少4.68%
证券之星 · 04-21
信邦制药(002390)3月31日股东户数7.04万户，较上期减少4.68%
信邦制药最新公告：2025年净利润同比增长18.65%拟10派0.6元
证券之星 · 04-20
信邦制药最新公告：2025年净利润同比增长18.65%拟10派0.6元
信邦制药：通过股份回购、现金分红等方式做好市值管理工作
证券之星 · 03-11
信邦制药：通过股份回购、现金分红等方式做好市值管理工作
股市必读：信邦制药（002390）2月25日董秘有最新回复
证券之星 · 02-26
股市必读：信邦制药（002390）2月25日董秘有最新回复
信邦制药：公司已建立常用中药材战略储备机制
证券之星 · 02-25
信邦制药：公司已建立常用中药材战略储备机制
信邦制药（002390）披露为控股子公司提供合计3亿元担保公告，2月4日股价上涨1.2%
证券之星 · 02-04
信邦制药（002390）披露为控股子公司提供合计3亿元担保公告，2月4日股价上涨1.2%
信邦制药：公司自产自销的中成药产品均已完成说明书中安全性内容的修订工作
证券之星 · 01-30
信邦制药：公司自产自销的中成药产品均已完成说明书中安全性内容的修订工作
信邦制药：贵州医科大学附属白云医院设立颐康医养中心
证券之星 · 01-26
信邦制药：贵州医科大学附属白云医院设立颐康医养中心
信邦制药：截至2024年度拥有23个国家医保目录品种
证券之星 · 01-26
信邦制药：截至2024年度拥有23个国家医保目录品种
股市必读：信邦制药（002390）1月23日董秘有最新回复
证券之星 · 01-26
股市必读：信邦制药（002390）1月23日董秘有最新回复
信邦制药最新公告：公司及下属子公司需补缴税款及滞纳金5078.69万元
证券之星 · 01-25
信邦制药最新公告：公司及下属子公司需补缴税款及滞纳金5078.69万元
信邦制药：公司目前暂未涉及您提及的技术运用
证券之星 · 01-23
信邦制药：公司目前暂未涉及您提及的技术运用
信邦制药：旗下医院开展美容医疗业务
证券之星 · 01-22
信邦制药：旗下医院开展美容医疗业务
加载更多
公司概况
公司名称：
贵州信邦制药股份有限公司
所属行业：
医药制造业
上市日期：
2010-04-16
主营业务：
贵州信邦制药股份有限公司的主营业务是医疗服务、医药流通及医药制造。公司的主要产品是益心舒胶囊、脉血康胶囊、关节克痹丸、银杏叶片、六味安消胶囊、贞芪扶正胶囊、益椹膏植物饮料、精山饮固体饮料、慧儿高植物固体饮料、器械、医疗服务。
发行价格：
33.00
{"stockData":{"symbol":"002390","market":"SZ","secType":"STK","nameCN":"信邦制药","latestPrice":3.03,"timestamp":1780378746000,"preClose":3.08,"halted":0,"volume":14097300,"delay":0,"changeRate":-0.0162,"floatShares":1928000000,"shares":1944000000,"eps":0.0657,"marketStatus":"交易中","change":-0.05,"latestTime":"06-02 13:39:06","open":3.06,"high":3.09,"low":3.02,"amount":43002400,"amplitude":0.0227,"askPrice":3.04,"askSize":2062,"bidPrice":3.03,"bidSize":8175,"shortable":0,"etf":0,"ttmEps":0.0657,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1780383600000},"marketStatusCode":2,"adr":0,"adjPreClose":3.08,"symbolType":"stock","openAndCloseTimeList":[[1780363800000,1780371000000],[1780376400000,1780383600000]],"highLimit":3.39,"lowLimit":2.77,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1943851868,"isCdr":false,"pbRate":0.88,"roa":"--","peRate":46.118721,"roe":"0.71%","epsLYR":0.0634,"committee":0.153274,"marketValue":5890000000,"turnoverRate":0.0073,"status":1,"floatMarketCap":5841000000},"requestUrl":"/m/hq/s/002390","defaultTab":"news","newsList":[{"id":"2635884807","title":"信邦制药（002390）披露2025年度股东会决议公告，5月13日股价下跌0.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635884807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635884807?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:09","pubTimestamp":1778666946,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，信邦制药报收于3.28元，较前一交易日下跌0.61%，最新总市值为63.76亿元。该股当日开盘3.3元，最高3.32元，最低3.26元，成交额达6918.27万元，换手率为1.1%。公司于近日披露《2025年度股东会决议的公告》。会议由公司第九届董事会召集，董事长安吉女士主持，出席股东及授权代表共314名，代表有表决权股份496,416,812股，占公司总股本的26.1767%。所有提案均获表决通过，其中部分议案获中小投资者多数同意。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300033857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002390","BK0146","BK0004","BK0056","BK0114","BK0096","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634236792","title":"股市必读：信邦制药（002390）5月11日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2634236792","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634236792?lang=zh_cn&edition=full","pubTime":"2026-05-12 01:13","pubTimestamp":1778519588,"startTime":"0","endTime":"0","summary":"截至2026年5月11日收盘，信邦制药报收于3.36元，上涨0.9%，换手率1.65%，成交量31.81万手，成交额1.06亿元。公司 2025 年营业收入下滑主要原因系医院及医药批发业务的经营规模受市场环境、行业政策等因素影响有所收缩。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200001295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0239","002390","BK0004","BK0056","BK0114","BK0028","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632725526","title":"每周股票复盘：信邦制药（002390）Q1净利增17.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632725526","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632725526?lang=zh_cn&edition=full","pubTime":"2026-05-03 04:10","pubTimestamp":1777752619,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，信邦制药报收于3.37元，较上周的3.16元上涨6.65%。本周，信邦制药4月30日盘中最高价报3.4元。股本股东变化股东户数变动截至2026年3月31日，信邦制药股东户数为7.04万户，较2025年12月31日减少3458.0户，减幅4.68%。业绩披露要点财务报告信邦制药2026年一季报显示，一季度主营收入12.63亿元，同比下降12.34%；归母净利润4865.65万元，同比上升17.97%；扣非净利润4714.52万元，同比上升14.78%；负债率17.06%，投资收益103.48万元，财务费用268.55万元，毛利率16.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300000890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0056","BK0028","002390","BK0096","BK0004","BK0146","BK0114","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631015596","title":"信邦制药(002390)3月31日股东户数7.04万户，较上期减少4.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631015596","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631015596?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:53","pubTimestamp":1777456399,"startTime":"0","endTime":"0","summary":"证券之星消息，近日信邦制药披露，截至2026年3月31日公司股东户数为7.04万户，较12月31日减少3458.0户，减幅为4.68%。在中药行业个股中，信邦制药股东户数高于行业平均水平，截至3月31日，中药行业平均股东户数为5.36万户。从股价来看，2025年12月31日至2026年3月31日，信邦制药区间涨幅为1.86%，在此期间股东户数减少3458.0户，减幅为4.68%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900056212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002390","BK0239","BK0004","BK0114","BK0056","BK0028","BK0096","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630306508","title":"图解信邦制药一季报：第一季度单季净利润同比增长17.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630306508","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630306508?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:25","pubTimestamp":1777375518,"startTime":"0","endTime":"0","summary":"证券之星消息，信邦制药2026年一季报显示，一季度公司主营收入12.63亿元，同比下降12.34%；归母净利润4865.65万元，同比上升17.97%；扣非净利润4714.52万元，同比上升14.78%；负债率17.06%，投资收益103.48万元，财务费用268.55万元，毛利率16.2%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800055384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002390"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629841982","title":"信邦制药：公司本报告期非经常性损益的主要构成为投资收益与子公司税率变化","url":"https://stock-news.laohu8.com/highlight/detail?id=2629841982","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629841982?lang=zh_cn&edition=full","pubTime":"2026-04-24 20:48","pubTimestamp":1777034888,"startTime":"0","endTime":"0","summary":"证券之星消息，信邦制药04月23日在投资者关系平台上答复投资者关心的问题。扣除非经常性损益的净利润较上年同期减少的主要原因为①非经常性损益本报告期为净收益，而上一年度为净损失②报告期计提信用减值损失及资产减值损失较上一年度增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400062344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0056","BK0096","BK0146","BK0114","BK0239","BK0028","002390","BK0004"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629889548","title":"信邦制药：公司2025年综合毛利率较去年同期略有上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2629889548","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629889548?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:51","pubTimestamp":1776934269,"startTime":"0","endTime":"0","summary":"证券之星消息，信邦制药04月23日在投资者关系平台上答复投资者关心的问题。信邦制药回复：您好，公司2025年综合毛利率较去年同期略有上升。公司及子公司的涉诉事项处于审理阶段，其结果存在不确定性，可能对公司的生产经营带来不利影响，目前公司及子公司的生产经营活动正常开展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300045699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002390","BK0239","BK0004","BK0114","BK0056","BK0028","BK0096","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629081767","title":"信邦制药(002390)3月31日股东户数7.04万户，较上期减少4.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629081767","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629081767?lang=zh_cn&edition=full","pubTime":"2026-04-21 17:17","pubTimestamp":1776763026,"startTime":"0","endTime":"0","summary":"证券之星消息，近日信邦制药披露，截至2026年3月31日公司股东户数为7.04万户，较12月31日减少3458.0户，减幅为4.68%。在中药行业个股中，信邦制药股东户数高于行业平均水平，截至3月31日，中药行业平均股东户数为5.36万户。从股价来看，2025年12月31日至2026年3月31日，信邦制药区间涨幅为1.86%，在此期间股东户数减少3458.0户，减幅为4.68%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100038975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","002390","BK0056","BK0004","BK0096","BK0028","BK0146","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628741249","title":"信邦制药最新公告：2025年净利润同比增长18.65%拟10派0.6元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628741249","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628741249?lang=zh_cn&edition=full","pubTime":"2026-04-20 18:20","pubTimestamp":1776680410,"startTime":"0","endTime":"0","summary":"信邦制药(002390.SZ)披露年报，2025年实现营业收入56.2亿元，同比下降6.84%；归母净利润1.2亿元，同比增长18.65%；基本每股收益0.06元。公司拟每10股派发现金红利0.6元(含税)。报告期内，归母净利润增长的主要原因为营业外支出事项较上年度减少，公司综合毛利率略有上升。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000028304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002390"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618947427","title":"信邦制药：通过股份回购、现金分红等方式做好市值管理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2618947427","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618947427?lang=zh_cn&edition=full","pubTime":"2026-03-11 20:52","pubTimestamp":1773233537,"startTime":"0","endTime":"0","summary":"在做好日常经营管理的基础上，公司通过实施股份回购、现金分红等方式以期做好市值管理工作，近五年实施完成两次股份回购计划，累计成交总金额6.55亿元；近五年实施权益分派六次，累积派发现金红利（含税）5.18亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100037415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002390","BK0004","BK0114","BK0146","BK0096","BK0239","BK0028","BK0056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614308570","title":"股市必读：信邦制药（002390）2月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2614308570","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614308570?lang=zh_cn&edition=full","pubTime":"2026-02-26 02:14","pubTimestamp":1772043253,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，信邦制药报收于3.41元，上涨1.79%，换手率1.78%，成交量34.35万手，成交额1.17亿元。当日关注点来自交易信息汇总：2月25日主力资金净流出86.12万元，散户资金净流入686.7万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600001228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002390","BK0004","BK0114","BK0146","BK0096","BK0239","BK0028","BK0056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614018697","title":"信邦制药：公司已建立常用中药材战略储备机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2614018697","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614018697?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:30","pubTimestamp":1772008241,"startTime":"0","endTime":"0","summary":"证券之星消息，信邦制药(002390)02月25日在投资者关系平台上答复投资者关心的问题。投资者提问：虽然贵公司的中药材基地大多数中药材都是自用，但是随着中药材疯狂涨价，贵公司的中药材基地是否越来越有价值了？信邦制药回复：您好，公司从道地药材基地采购的中药材用于自身生产中药饮片和中成药。公司已建立常用中药材战略储备机制，对冲中药材市场波动风险，可以有效降低中药材价格异动对公司经营的影响。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500025560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0146","002390","BK0004","BK0239","BK0028","BK0096","BK0056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608360070","title":"信邦制药（002390）披露为控股子公司提供合计3亿元担保公告，2月4日股价上涨1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608360070","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608360070?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:28","pubTimestamp":1770215299,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，信邦制药报收于3.36元，较前一交易日上涨1.2%，最新总市值为65.31亿元。近日，贵州信邦制药股份有限公司披露《关于为控股子公司提供担保的公告》。公告显示，公司于2026年2月3日与光大银行贵阳分行签订担保合同，为其控股子公司贵州同德药业股份有限公司提供4,000万元连带责任保证担保，担保期限为主债务履行期届满之日起三年；同时为另一控股子公司贵州科开医药有限公司提供26,000万元连带责任保证担保，担保期限相同。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002390","BK0239","BK0004","BK0114","BK0056","BK0028","BK0096","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607068703","title":"信邦制药：公司自产自销的中成药产品均已完成说明书中安全性内容的修订工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2607068703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607068703?lang=zh_cn&edition=full","pubTime":"2026-01-30 08:33","pubTimestamp":1769733186,"startTime":"0","endTime":"0","summary":"证券之星消息，信邦制药01月29日在投资者关系平台上答复投资者关心的问题。公司未来也将持续关注行业的相关动态和变化，做好日常经营管理，不断深化和挖掘产业发展潜力，确保公司在市场竞争中保持优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000007588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0114","BK0004","BK0146","BK0239","BK0056","002390","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606290574","title":"信邦制药：贵州医科大学附属白云医院设立颐康医养中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2606290574","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606290574?lang=zh_cn&edition=full","pubTime":"2026-01-26 16:06","pubTimestamp":1769414779,"startTime":"0","endTime":"0","summary":"证券之星消息，信邦制药(002390)01月26日在投资者关系平台上答复投资者关心的问题。投资者提问：人口老龄化严重，贵公司在养老康复服务方面有哪些布局？信邦制药回复：您好，公司下属的贵州医科大学附属白云医院设立有颐康医养中心，致力为失能、半失能、术后需康复、生活难自理等人员提供全方位、专业化、多层次、高品质的健康养老服务；公司下属的贵州医科大学附属乌当医院与本地养老院也有长期的合作，为其提供医疗、康复及护理等服务。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600015663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0004","BK0028","BK0146","002390","BK0114","BK0096","BK0056","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606905172","title":"信邦制药：截至2024年度拥有23个国家医保目录品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2606905172","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606905172?lang=zh_cn&edition=full","pubTime":"2026-01-26 16:06","pubTimestamp":1769414778,"startTime":"0","endTime":"0","summary":"证券之星消息，信邦制药(002390)01月26日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司中药业务到目前已经有多少个加入国家医保目录品种？信邦制药回复：您好，截至2024年度，在中成药方面，公司拥有11个国家基药目录品种，23个国家医保目录品种，主要品种益心舒胶囊、脉血康胶囊、关节克痹丸（独家品种）、银杏叶片、六味安消胶囊、贞芪扶正胶囊均在国家医保目录中。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600015657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0114","BK0028","BK0146","BK0056","BK0004","BK0239","002390"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606878263","title":"股市必读：信邦制药（002390）1月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606878263","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606878263?lang=zh_cn&edition=full","pubTime":"2026-01-26 01:42","pubTimestamp":1769362937,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，信邦制药报收于3.43元，上涨2.69%，换手率2.88%，成交量55.52万手，成交额1.89亿元。关于补缴税款的公告贵州信邦制药股份有限公司及下属子公司根据主管税务机关要求对涉税事项开展自查，需补缴税款及滞纳金合计5,078.69万元，其中公司补缴269.57万元，下属子公司补缴4,809.12万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600000740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002390","BK0239","BK0004","BK0114","BK0056","BK0028","BK0096","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606319254","title":"信邦制药最新公告：公司及下属子公司需补缴税款及滞纳金5078.69万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606319254","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606319254?lang=zh_cn&edition=full","pubTime":"2026-01-25 17:30","pubTimestamp":1769333458,"startTime":"0","endTime":"0","summary":"信邦制药(002390.SZ)公告称，经自查，公司及下属子公司需补缴税款及滞纳金5078.69万元。上述补缴税款及滞纳金将计入公司2025年当期损益。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500007586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0056","BK0004","BK0114","BK0028","BK0146","002390","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605142018","title":"信邦制药：公司目前暂未涉及您提及的技术运用","url":"https://stock-news.laohu8.com/highlight/detail?id=2605142018","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605142018?lang=zh_cn&edition=full","pubTime":"2026-01-23 16:30","pubTimestamp":1769157039,"startTime":"0","endTime":"0","summary":"证券之星消息，信邦制药01月23日在投资者关系平台上答复投资者关心的问题。AI技术赋能提升医疗服务效率与质量。作为贵州省医药流通龙头，公司覆盖全省95%以上等级医院及45%基层医院。公司始终对各种新技术在医疗领域的发展和运用保持关注，未来也将结合公司实际情况，对相关技术在公司业务方面的运用可能性进行积极探索。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300024295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0056","BK0096","002390","BK0114","BK0239","BK0004","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605016432","title":"信邦制药：旗下医院开展美容医疗业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2605016432","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605016432?lang=zh_cn&edition=full","pubTime":"2026-01-22 08:48","pubTimestamp":1769042889,"startTime":"0","endTime":"0","summary":"证券之星消息，信邦制药(002390)01月21日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司旗下医院是否有美容医疗的业务？信邦制药回复：您好，公司下属贵州医科大学附属乌当医院设有整形科，目前开展有眼鼻整形、注射微整形、注射水光针、光子嫩肤等项目；下属仁怀新朝阳医院有限公司设有医美科，科室以整形美容与皮肤美容为特色构建一体化诊治体系，目前开展有面部整形、皮肤管理等项目。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200006306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","BK0004","BK0114","BK0096","BK0146","BK0028","BK0239","BK0056","002390"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780378748437,"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0686},{"period":"3month","weight":-0.0461},{"period":"6month","weight":-0.1954},{"period":"1year","weight":-0.1033},{"period":"ytd","weight":-0.0253}],"compareEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.0132},{"period":"3month","weight":-0.0158},{"period":"6month","weight":0.0463},{"period":"1year","weight":0.2122},{"period":"ytd","weight":0.0224}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"贵州信邦制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"70442人(较上一季度减少4.68%)","perCapita":"27367股","listingDate":"2010-04-16","address":"贵州省黔南布依族苗族自治州罗甸县龙坪镇信邦大道48号","registeredCapital":"194385万元","survey":" 贵州信邦制药股份有限公司的主营业务是医疗服务、医药流通及医药制造。公司的主要产品是益心舒胶囊、脉血康胶囊、关节克痹丸、银杏叶片、六味安消胶囊、贞芪扶正胶囊、益椹膏植物饮料、精山饮固体饮料、慧儿高植物固体饮料、器械、医疗服务。","listedPrice":33},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信邦制药(002390)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信邦制药(002390)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信邦制药,002390,信邦制药股票,信邦制药股票老虎,信邦制药股票老虎国际,信邦制药行情,信邦制药股票行情,信邦制药股价,信邦制药股市,信邦制药股票价格,信邦制药股票交易,信邦制药股票购买,信邦制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信邦制药(002390)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信邦制药(002390)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}